Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans - Wikidata - wikimedia - TriplyDB

Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans

Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans

http://www.wikidata.org/entity/Q35759011

about

Adverse effects of pefloxacin in irradiated C3H/HeN mice: correction with glucan therapy Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model Chemotherapeutics Evaluation of quinolones in experimental animal models of infections.Characterization of a new norfloxacin metabolite monitored during a bioequivalence study by means of mass spectrometry and quantum computation.Oral Bioavailability and Plasma Disposition of Pefloxacin in Healthy Broiler Chickens.Determination of pefloxacin concentration in mesenteric lymph nodes by high-performance chromatography.Proteoglycan and collagen biochemical variations during fluoroquinolone-induced chondrotoxicity in mice Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen.Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group Penetration of pefloxacin into bronchial secretions Activities of pefloxacin and ciprofloxacin against experimental malaria in mice.Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients Hepatobiliary kinetics and excretion of ciprofloxacin.Recovery of pefloxacin in saliva and feces and its action on oral and fecal floras of healthy volunteers.Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.Metabolism and disposition of amifloxacin in laboratory animals Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers.Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals.Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data.Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.Pharmacokinetics of temafloxacin in humans after single oral doses.Tentative disk diffusion susceptibility interpretive criteria for pefloxacin Pharmacokinetics of quinolones: newer aspects.Potential role of fluoroquinolones in the treatment of bacterial meningitis.Physiologically based pharmacokinetic tissue compartment model selection in drug development and risk assessment The 4-quinolone antibiotics: past, present, and future.Effect of trikatu pretreatment on the pharmacokinetics of pefloxacin administered orally in mountain Gaddi goats.The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics.Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds.Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.Difloxacin metabolism and pharmacokinetics in humans after single oral doses

P2860

Q24679877-C04ADD2E-9FFD-414B-86D1-17DB5B3B2A41 Q28320245-95BFD21E-C5AB-4C08-A7B9-C9194A8EF7C4 Q28360207-6F44B82C-59A0-479D-88ED-9D8DE71BCF72 Q28361126-5C659863-8F97-46E6-823A-C114472DF8A7 Q28378635-45441312-F732-4033-9075-CBB5046AC76F Q30047670-066BE327-B478-401C-8C96-4BE9E87346F9 Q30446615-C7AD46C9-0340-42EF-BCF9-7D10A9507AF5 Q33338086-741DA3B9-D102-4137-8C07-4CE598C71182 Q33720333-A3AA7493-4D7C-4A2F-A440-34528D0881D2 Q33751873-434C270A-7BCD-4C7E-A558-EF3F89E64D97 Q33978259-4EBD06B7-404F-482F-938A-2747698C0A06 Q33979092-35BA9F1A-3317-4845-94C1-E1A31D12D66D Q35111149-14B98A23-2892-42A1-A27F-CB082FA4BA01 Q35245057-6979DF05-2BC0-4B2B-BEAA-B21D982F5DF1 Q35284671-C01D16CF-E35A-452E-91CD-DC2AC621A9C1 Q35285443-885C811A-9117-4A16-836B-93B726911E61 Q35312303-65B08411-9840-41FB-91BC-F890D4927499 Q35543011-B503F07C-DFC2-4004-A9A5-082C89CD41E2 Q35543537-E8C06931-0465-4D13-9365-9EDA347B1CCD Q35572870-259C01F2-11DB-4DB4-86F5-70CD7B173A75 Q35573087-9A02235B-57E4-4F50-8F92-04334353A0C3 Q35573196-CDEFC058-1FE0-4CE5-B5C0-AA975D81CBDC Q35644448-09C349CD-90ED-406E-9D66-9ACFB60413ED Q35651641-5EE17B8B-DFB3-4454-838C-B6EE70359AA8 Q35811353-C314830B-F715-4DBD-AB7A-625B180A42C8 Q35893937-6D5B30F6-DA2A-4BF1-B463-ADC5F79694DC Q36474398-F1C76E8B-046D-49E5-B5AE-24B85069A054 Q36718935-0C144CF9-6F0E-4633-8E3D-3B032CA201CC Q36753040-B1FAE7FA-473A-44C4-95B3-445ECEE37CCF Q37209701-A43A8EC9-9989-4255-89CB-C9AB4D5DAD4C Q37222580-8DCEEED7-CF9B-4E93-9642-E57127C8CDF0 Q37222584-68297E4D-BA2B-4592-B07A-744041FFD280 Q37942029-706D3E9A-8EC6-44BB-BC5C-55C33F96AFA5 Q39314610-844D9A73-86B2-4B00-8AE4-4568956AABD3 Q39636707-C10A49F9-B477-4A7F-B172-FA338FAC12D5 Q39637673-D48A7037-BABB-4C2F-A67A-1597B8B67D44 Q39730719-75056A3A-3161-45B1-A1E3-C8F73E1FB0C5 Q39785242-65A42DE1-7B4A-4779-AE2F-787259B0FE6C Q39827591-30C31871-6213-4A52-B3E8-ECFD090C5146 Q39834941-764E3C20-E394-484E-B88A-765F1453DFAC

P2860

Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans

http://www.wikidata.org/entity/Q35759011

description

1984 nî lūn-bûn

@nan

1984年の論文

@ja

1984年論文

@yue

1984年論文

@zh-hant

1984年論文

@zh-hk

1984年論文

@zh-mo

1984年論文

@zh-tw

1984年论文

@wuu

1984年论文

@zh

1984年论文

@zh-cn

name

Absorption, distribution, meta ...... ats, dogs, monkeys, and humans

@ast

Absorption, distribution, meta ...... ats, dogs, monkeys, and humans

@en

type

label

Absorption, distribution, meta ...... ats, dogs, monkeys, and humans

@ast

Absorption, distribution, meta ...... ats, dogs, monkeys, and humans

@en

prefLabel

Absorption, distribution, meta ...... ats, dogs, monkeys, and humans

@ast

Absorption, distribution, meta ...... ats, dogs, monkeys, and humans

@en

P1433

Q35759011-6F1B0692-83A9-44D1-A7E4-428CA4D337EC

P1476

Q35759011-8BE70920-614F-430C-A701-DE418252ED58

P2093

Q35759011-0D74F74D-D51A-4513-A1AE-A6496E29EA9F

Q35759011-7099CC44-98F7-4090-B356-B0D657C90DEA

Q35759011-BF28C7A2-2870-439A-8AEA-CDC15B406AC8

P2860

Q35759011-0FA2C9FA-507D-4C5F-B343-E8444368DDE0

Q35759011-37C67577-349D-457E-A226-CFBC72395EF6

Q35759011-43C8745F-B720-4ECD-B262-FBFD9267461A

P304

Q35759011-291C72E3-CD5A-4639-B52C-15445EBE4448

P31

Q35759011-A50E579F-B170-4501-8B05-810FB7BA36DC

P356

Q35759011-4D1DAB6B-F0B8-4EF5-A28C-FC16E4B395BE

P407

Q35759011-AF4BF01A-B725-4EB8-BE76-79F2E60092A3

P433

Q35759011-B5D96170-A16C-4DB2-8B73-3779D15BB1DF

P478

Q35759011-E9C94099-1537-4F2B-A906-7EC1F66F871C

P577

Q35759011-91F811D6-E715-4092-9B18-7030B27D72BF

P698

Q35759011-E842EF9D-4FA0-4E6A-8F43-1A6B965C66A1

P932

Q35759011-A9ED282B-5E2C-4D14-A0B0-7F99424ADB27

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Absorption, distribution, meta ...... ats, dogs, monkeys, and humans

@en

P2093

Goueffon Y

http://www.w3.org/2001/XMLSchema#string

Montay G

http://www.w3.org/2001/XMLSchema#string

Roquet F

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys.

In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

[Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].

P304

463-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.25.4.463

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

1984-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

6587830

http://www.w3.org/2001/XMLSchema#string

P932

185553

http://www.w3.org/2001/XMLSchema#string